A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1659-1668

  Colonna, Lucien ^a   Andersen, Henning Friis ^b   Reines, Elin Heldbo ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b H LUNDBECK A S   (Denmark)

Author keywords

Antidepressant; CGI S; Long term treatment; MADRS; Moderate depression; Remission; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM;

ABDOMINAL PAIN; ACCIDENT; ADULT; AGED; ANXIETY DISORDER; BACKACHE; BRONCHITIS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FATIGUE; FEMALE; HEADACHE; HUMAN; INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PARAMETER; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; RHINITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDE; TREATMENT OUTCOME; VARIANCE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 27144516427     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65484     Document Type: Conference Paper

References (24)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003;289:3095-105
2. Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92
3. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994; 8:48-53
4. Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, WFSBP Task Force on Treatment. Guidelines for unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002;3:69-86
5. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-10
6. Norman TR, Olver JS. New formulations of existing anti-depressants: advantages in the management of depression. CNS Drugs 2004;18:505-20
7. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
8. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
9. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7
10. Moore N, Verdoux H, Fantinoe B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
11. Bech P, Tanghøj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharm 2004;7:283-90
12. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psychiatry Clin Prac 2002;6:243-4
13. Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Prac 2003;7:259-68
14. Waugh J, Goa KL. Escitalopram. A review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17:343-62
15. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305-10
16. World Medical Association (WMA). Declaration of Helsinki: ethical principles for medical research involving human subjects, 1964
17. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382-9
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
19. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare. DHEW Publication No. (ADM) 218-222. Kensington, MD: The George Washington University; 1976
20. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994;4:283-4
21. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? Br Med J 2001;322:989-91
22. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Suppl 1):40-4
23. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? - a pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55
24. Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001;16:105-14